The Chemours Company Reports Third Quarter 2024 Results and Outlines Refreshed Corporate Strategy
Chemours reported Q3 2024 financial results with Net Sales of $1.5 billion, up 1% year-over-year. The company recorded a Net Loss of $27 million ($0.18 per share), including a $56 million non-cash impairment charge, compared to Net Income of $12 million in Q3 2023. Adjusted EBITDA was $208 million, slightly down from $211 million last year.
The Thermal & Specialized Solutions segment achieved record Q3 sales, with Opteon™ Refrigerants growing 21% year-over-year. The company outlined a refreshed corporate strategy focusing on operational excellence, targeting over $250 million in cost savings through 2027.
Chemours ha riportato i risultati finanziari del terzo trimestre 2024, con vendite nette di 1,5 miliardi di dollari, in aumento dell'1% rispetto all'anno precedente. L'azienda ha registrato una perdita netta di 27 milioni di dollari (0,18 dollari per azione), inclusa una svalutazione non monetaria di 56 milioni di dollari, rispetto a un utile netto di 12 milioni di dollari nel terzo trimestre 2023. L’EBITDA rettificato è stato di 208 milioni di dollari, leggermente in calo rispetto ai 211 milioni di dollari dell'anno scorso.
Il segmento Soluzioni Termiche e Specializzate ha raggiunto vendite record nel terzo trimestre, con gli Refrigeranti Opteon™ in crescita del 21% rispetto all'anno precedente. L'azienda ha delineato una strategia aziendale rinnovata focalizzata sull'eccellenza operativa, mirando a oltre 250 milioni di dollari di risparmi sui costi entro il 2027.
Chemours informó los resultados financieros del tercer trimestre de 2024, con ventas netas de 1.5 mil millones de dólares, un incremento del 1% en comparación al año anterior. La compañía registró una pérdida neta de 27 millones de dólares (0.18 dólares por acción), incluyendo un cargo por deterioro no monetario de 56 millones de dólares, en comparación con una ganancia neta de 12 millones de dólares en el tercer trimestre de 2023. El EBITDA ajustado fue de 208 millones de dólares, ligeramente inferior a los 211 millones de dólares del año pasado.
El segmento de Soluciones Térmicas y Especializadas logró ventas récord en el tercer trimestre, con los Refrigerantes Opteon™ creciendo un 21% en comparación al año anterior. La empresa presentó una estrategia corporativa renovada centrada en la excelencia operativa, con el objetivo de más de 250 millones de dólares en ahorros de costos para 2027.
케모어스(Chemours)는 2024년 3분기 재무 결과를 발표했으며, 순매출이 15억 달러로 전년 대비 1% 증가했습니다. 회사는 순손실 2700만 달러($0.18 주당) 을 기록했으며, 여기에는 5600만 달러의 비현금 손상 차감이 포함됩니다. 이는 2023년 3분기 순이익 1200만 달러와 비교됩니다. 조정된 EBITDA는 2억 800만 달러로, 작년의 2억 1100만 달러에서 약간 감소했습니다.
열 및 전문 솔루션 부문은 3분기 기록적인 판매를 달성했으며, 오프테온™ 냉매가 전년 대비 21% 성장했습니다. 회사는 2027년까지 2억 5000만 달러 이상의 비용 절감을 목표로 하는 운영 우수성에 중점을 둔 새롭고 신선한 기업 전략을 설명했습니다.
Chemours a publié ses résultats financiers pour le troisième trimestre de 2024, avec des ventes nettes de 1,5 milliard de dollars, en hausse de 1 % par rapport à l'année précédente. L'entreprise a enregistré une perte nette de 27 millions de dollars (0,18 dollar par action), y compris une charge d'amortissement non monétaire de 56 millions de dollars, par rapport à un bénéfice net de 12 millions de dollars au troisième trimestre 2023. L'EBITDA ajusté s'élevait à 208 millions de dollars, légèrement en baisse par rapport à 211 millions de dollars l'année dernière.
Le segment Solutions Thermiques et Spécialisées a atteint des ventes records au troisième trimestre, avec les réfrigérants Opteon™ affichant une croissance de 21 % par rapport à l'année précédente. L'entreprise a présenté une stratégie d'entreprise renouvelée axée sur l'excellence opérationnelle, visant plus de 250 millions de dollars d'économies de coûts d'ici 2027.
Chemours hat die Finanzzahlen des dritten Quartals 2024 veröffentlicht, mit Nettoverkaufszahlen von 1,5 Milliarden Dollar, was einem Anstieg von 1 % im Vergleich zum Vorjahr entspricht. Das Unternehmen meldete einen Nettoverlust von 27 Millionen Dollar (0,18 Dollar pro Aktie), einschließlich einer nicht zahlungswirksamen Abschreibung von 56 Millionen Dollar, im Vergleich zu einem Nettogewinn von 12 Millionen Dollar im dritten Quartal 2023. Das bereinigte EBITDA lag bei 208 Millionen Dollar und war damit leicht niedriger als die 211 Millionen Dollar im letzten Jahr.
Das Segment Thermische & Spezialisierte Lösungen erzielte im dritten Quartal Rekordverkäufe, wobei Opteon™ Kältemittel um 21 % wuchsen im Jahresvergleich. Das Unternehmen umriss eine erneuerte Unternehmensstrategie, die sich auf betriebliche Exzellenz konzentriert, mit dem Ziel, bis 2027 über 250 Millionen Dollar an Kosteneinsparungen zu erreichen.
- Record Q3 sales in Thermal & Specialized Solutions segment with 21% growth in Opteon™ Refrigerants
- Titanium Technologies segment Adjusted EBITDA increased 23% to $85 million
- Planned cost savings of over $250 million through 2027
- Strong liquidity position of $1.2 billion
- Net Loss of $27 million compared to Net Income of $12 million in Q3 2023
- $56 million non-cash impairment charge in Advanced Performance Materials segment
- Advanced Performance Materials Adjusted EBITDA decreased 43% to $39 million
- High net leverage ratio of 4.4x trailing twelve-month Adjusted EBITDA
Insights
The Q3 2024 results show mixed performance across segments. Net sales of
The new corporate strategy focusing on
The refrigerants market dynamics present both opportunities and challenges. While Opteon™ shows strong momentum from low-GWP adoption, Freon™ faces pricing pressure from high HFC inventory levels. The
Key Third Quarter 2024 Results & Highlights
-
Net Sales of
, in line with the corresponding prior-year quarter, with TSS achieving record third quarter Net Sales, driven by year-over-year growth of$1.5 billion 21% in Opteon™ Refrigerants -
Net Loss attributable to Chemours of
or$27 million per diluted share reflecting a non-cash impairment charge of$0.18 1, compared with a Net Income attributable to Chemours of$56 million , or$12 million per diluted share, in the corresponding prior-year quarter$0.08 -
Adjusted Net Income2 of
, or$61 million per diluted share, compared with$0.40 , or$65 million per diluted share, in the corresponding prior-year quarter$0.43 -
Adjusted EBITDA2,3 of
compared to$208 million 4 million in the corresponding prior-year quarter$211 -
Cash returned to shareholders through dividends of
in the quarter$38 million
“In the third quarter, we delivered strong results, meeting our Net Sales expectations and exceeding our Adjusted EBITDA expectations. We set a Net Sales record for TSS5, driven by robust
Total Chemours
|
Q3 2024 |
|
Q3 2023 |
|
Y-o-Y % ∆ |
|
Q2 2024 |
|
Q-o-Q % ∆ |
|
Net Sales (millions) |
|
|
|
|
(2)% |
|||||
Adjusted EBITDA (millions) |
|
|
(1)% |
|
|
Third quarter 2024 Net Sales of
Third quarter 2024 Net Loss attributable to Chemours was
Thermal & Specialized Solutions
|
Q3 2024 |
|
Q3 2023 |
|
Y-o-Y % ∆ |
|
Q2 2024 |
|
Q-o-Q % ∆ |
|
Net Sales (millions) |
|
|
|
|
(10)% |
|||||
Opteon™ Refrigerants |
|
|
|
|
(10)% |
|||||
Freon™ Refrigerants |
|
|
(14)% |
|
(16)% |
|||||
Foam, Propellants & Other |
|
|
|
|
(4)% |
|||||
Adjusted EBITDA (millions) |
|
|
(13)% |
|
(12)% |
|||||
Adjusted EBITDA Margin |
|
|
(6) ppts |
|
(0) ppts |
TSS segment third quarter 2024 Net Sales were
TSS segment third quarter 2024 adjusted EBITDA decreased
On a sequential basis, Net Sales decreased by
Titanium Technologies
|
Q3 2024 |
|
Q3 2023 |
|
Y-o-Y % ∆ |
|
Q2 2024 |
|
Q-o-Q % ∆ |
|
Net Sales (millions) |
|
|
(2)% |
|
|
|||||
Adjusted EBITDA (millions) |
|
|
|
|
|
|||||
Adjusted EBITDA Margin |
|
|
3 ppts |
|
1 ppt |
TT segment third quarter 2024 Net Sales were
Adjusted EBITDA increased
On a sequential basis, Net Sales increased
Advanced Performance Materials
|
Q3 2024 |
|
Q3 2023 |
|
Y-o-Y % ∆ |
|
Q2 2024 |
|
Q-o-Q % ∆ |
|
Net Sales (millions) |
|
|
|
|
|
|||||
Advanced Materials |
|
|
(3)% |
|
|
|||||
Performance Solutions |
|
|
|
|
|
|||||
Adjusted EBITDA (millions) |
|
|
(43)% |
|
(13)% |
|||||
Adjusted EBITDA Margin |
|
|
(9) ppts |
|
(2) ppts |
APM segment third quarter 2024 Net Sales were
APM segment third quarter 2024 adjusted EBITDA decreased
On a sequential basis, Net Sales increased by
Other Segment
The Performance Chemicals and Intermediates business in the Company’s Other Segment had Net Sales and Adjusted EBITDA for the third quarter 2024 of
Corporate Expenses6
Corporate Expenses were a
Liquidity
As of September 30, 2024, consolidated gross debt was
Cash provided by operating activities for the third quarter of 2024 was
Fourth Quarter 2024 Outlook
In the fourth quarter, TSS anticipates a sequential low-teens Net Sales decline driven by refrigerant seasonality, while expecting TSS to maintain overall double-digit year-over-year growth in Opteon™ Refrigerants. TSS Adjusted EBITDA is expected to decrease in the low
TT expects a mid- to high-single digit sequential Net Sales decline, with seasonality driving lower volumes, as well as impacts from mix of regional sales. Adjusted EBITDA is expected to decrease between mid-to-high teens, consistent with the referenced sequentially-lower volumes and mix.
APM expects a low-single digit Net Sales decline in the fourth quarter, driven by macro weakness in Advanced Materials end markets slightly offsetting increases in Performance Solutions. Adjusted EBITDA is anticipated to be broadly flat sequentially due to the favorable contribution from Performance Solutions sales and cost reduction efforts across the business.
The Company anticipates a consolidated Net Sales decrease in the mid to high-single digits sequentially, with consolidated Adjusted EBITDA down in the high teens to low
Overall unrestricted cash in the fourth quarter is anticipated to remain generally in line with the third quarter, generating a positive operating cash flow. Cash uses in the fourth quarter will be concentrated around planned maintenance activities and the expansion of TSS’s production site at
Chemours Corporate Strategy Update
Chemours today also outlined a refreshed corporate strategy, “Pathway to Thrive,” which builds on the Company’s strong foundation in TSS, TT, and APM, and includes actionable steps to create short- and long-term value centered around four pillars: Operational Excellence, Enabling Growth, Portfolio Management and Strengthening the Long Term.
“Over the last several months, we have taken a hard look at the business to develop a strategy that will unlock value for shareholders and build on our commitments to the customers and communities we serve,” said Denise Dignam. “We have three strong businesses, a strong management team, good operational execution, and clear competitive differentiators that position us well to execute. Our strategy balances growth with disciplined capital allocation, including ongoing cost actions that are core to how we run our business.”
Operational Excellence: Chemours expects to achieve incremental run-rate cost savings of greater than
The Company will apply a programmatic approach to achieve these targets, leveraging its manufacturing excellence, standardized operating model and continuous improvement to adapt to changing markets. Given progress on cost-out execution efforts as of the third quarter of 2024, the Company anticipates achieving
Enabling Growth: Chemours is committed to strategically investing in high-return, innovative growth initiatives across its portfolio, targeting a sales CAGR exceeding
Portfolio Management: The Company is strategically optimizing its portfolio by shifting its focus from products to applications in higher-growth, higher-margin markets. This will be paired with regular holistic portfolio analysis focused on asset base returns in order to drive shareholder value. The Company will also evaluate its asset footprint to ensure the asset base is best positioned to meet the Company’s future needs.
Strengthening the Long Term: Chemours has made measurable progress resolving legacy liabilities, highlighted in the national public water systems settlement finalized earlier this year. The Company will continue to prioritize seeking reasonable resolutions for the benefit of Chemours’ shareholders and other stakeholders. Chemours will also maintain its commitment to responsible manufacturing and continue to engage in advocacy efforts that create global awareness, as well as regulations and policies globally that recognize the criticality of the Company’s chemistries.
Conference Call
As previously announced, Chemours will hold a conference call and webcast on November 4, 2024, at 8:00 AM Eastern Standard Time. Access to the webcast and materials can be accessed by visiting the Events & Presentations page of Chemours’ investor website, investors.chemours.com. A webcast replay of the conference call will be available on Chemours’ investor website.
_________________ | ||||||||||
1 During the third quarter of 2024, the Company reviewed recently released third-party industry projections, which for hydrogen now reflect lower end-market demand as well as slower market growth through 2030 and a more uncertain long-term growth trajectory beyond 2030. In response to these negative market outlook developments as well as increased commercial headwinds due to limited cyclical end-markets recovery and competitive intensity, the Company has revised its financial projections for the Advanced Performance Materials business which includes reductions to its investment plans. The Company concluded that these market developments, as well as the Company's revised financial projections to reflect these events, represented a triggering event for the Company's Advanced Performance Materials reporting unit and associated goodwill, as well as the related asset group, during the third quarter of 2024. As a result of this triggering event, a non-cash charge of |
||||||||||
2 Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)”. |
||||||||||
3 Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. See the corresponding reconciliation referenced in footnote #1. |
||||||||||
4 The Company revised its September 30, 2023 non-GAAP Adjusted EBITDA calculation to (1) remove previous adjustments related to the write-off of certain raw materials and stores inventories and (2) correct the understatement of accrued liabilities for steam supplier contract litigation stemming from the decommissioning of the Kuan Yin, |
||||||||||
5 For the third quarter as a segment. |
||||||||||
6 2024 consolidated Adjusted EBITDA also reflect additional unallocated costs of |
||||||||||
7 Cost savings applied on an Adjusted EBITDA basis with benefits not being realized until early 2025. |
||||||||||
8 Expanding upon the |
||||||||||
9 Restructuring costs associated with the APM business and corporate overheads are captured as a part of the 2024 Restructuring Program in the third quarter of 2024. |
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers’ biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in
For more information, visit chemours.com or follow us on X (formerly Twitter) @Chemours or LinkedIn.
Non-GAAP Financial Measures
We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.
Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the fourth quarter of 2024 and the Company’s strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, remediation of material weaknesses and internal control over financial reporting, changes in environmental regulations in the
The Chemours Company |
||||||||||||||||
Consolidated Statements of Operations (Unaudited) |
||||||||||||||||
(Dollars in millions, except per share amounts) |
||||||||||||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net sales |
|
$ |
1,501 |
|
|
$ |
1,487 |
|
|
$ |
4,388 |
|
|
$ |
4,666 |
|
Cost of goods sold |
|
|
1,215 |
|
|
|
1,214 |
|
|
|
3,510 |
|
|
|
3,615 |
|
Gross profit |
|
|
286 |
|
|
|
273 |
|
|
|
878 |
|
|
|
1,051 |
|
Selling, general, and administrative expense |
|
|
135 |
|
|
|
165 |
|
|
|
416 |
|
|
|
1,067 |
|
Research and development expense |
|
|
29 |
|
|
|
28 |
|
|
|
83 |
|
|
|
82 |
|
Restructuring, asset-related, and other charges |
|
|
45 |
|
|
|
126 |
|
|
|
52 |
|
|
|
141 |
|
Goodwill impairment charge |
|
|
56 |
|
|
|
— |
|
|
|
56 |
|
|
|
— |
|
Total other operating expenses |
|
|
265 |
|
|
|
319 |
|
|
|
607 |
|
|
|
1,290 |
|
Equity in earnings of affiliates |
|
|
11 |
|
|
|
13 |
|
|
|
34 |
|
|
|
38 |
|
Interest expense, net |
|
|
(69 |
) |
|
|
(55 |
) |
|
|
(197 |
) |
|
|
(145 |
) |
Loss on extinguishment of debt |
|
|
— |
|
|
|
(1 |
) |
|
|
— |
|
|
|
(1 |
) |
Other income, net |
|
|
7 |
|
|
|
102 |
|
|
|
10 |
|
|
|
100 |
|
(Loss) income before income taxes |
|
|
(30 |
) |
|
|
13 |
|
|
|
118 |
|
|
|
(247 |
) |
(Benefit from) provision for income taxes |
|
|
(3 |
) |
|
|
1 |
|
|
|
24 |
|
|
|
(28 |
) |
Net (loss) income |
|
|
(27 |
) |
|
|
12 |
|
|
|
94 |
|
|
|
(219 |
) |
Less: Net income attributable to non-controlling interests |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
Net (loss) income attributable to Chemours |
|
$ |
(27 |
) |
|
$ |
12 |
|
|
$ |
94 |
|
|
$ |
(220 |
) |
Per share data |
|
|
|
|
|
|
|
|
||||||||
Basic (loss) earnings per share of common stock |
|
$ |
(0.18 |
) |
|
$ |
0.08 |
|
|
$ |
0.63 |
|
|
$ |
(1.47 |
) |
Diluted (loss) earnings per share of common stock |
|
|
(0.18 |
) |
|
|
0.08 |
|
|
|
0.63 |
|
|
|
(1.47 |
) |
The Chemours Company |
||||||||
Consolidated Balance Sheets (Unaudited) |
||||||||
(Dollars in millions, except per share amounts) |
||||||||
|
|
September 30, 2024 |
|
December 31, 2023 |
||||
Assets |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
596 |
|
|
$ |
1,203 |
|
Restricted cash and restricted cash equivalents |
|
|
20 |
|
|
|
604 |
|
Accounts and notes receivable, net |
|
|
951 |
|
|
|
610 |
|
Inventories |
|
|
1,438 |
|
|
|
1,352 |
|
Prepaid expenses and other |
|
|
75 |
|
|
|
66 |
|
Total current assets |
|
|
3,080 |
|
|
|
3,835 |
|
Property, plant, and equipment |
|
|
9,545 |
|
|
|
9,412 |
|
Less: Accumulated depreciation |
|
|
(6,372 |
) |
|
|
(6,196 |
) |
Property, plant, and equipment, net |
|
|
3,173 |
|
|
|
3,216 |
|
Operating lease right-of-use assets |
|
|
254 |
|
|
|
260 |
|
Goodwill |
|
|
46 |
|
|
|
102 |
|
Other intangible assets, net |
|
|
3 |
|
|
|
3 |
|
Investments in affiliates |
|
|
190 |
|
|
|
158 |
|
Restricted cash and restricted cash equivalents |
|
|
50 |
|
|
|
— |
|
Other assets |
|
|
667 |
|
|
|
677 |
|
Total assets |
|
$ |
7,463 |
|
|
$ |
8,251 |
|
Liabilities |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Accounts payable |
|
$ |
1,069 |
|
|
$ |
1,159 |
|
Compensation and other employee-related cost |
|
|
89 |
|
|
|
89 |
|
Short-term and current maturities of long-term debt |
|
|
53 |
|
|
|
51 |
|
Current environmental remediation |
|
|
119 |
|
|
|
129 |
|
Other accrued liabilities |
|
|
447 |
|
|
|
1,058 |
|
Total current liabilities |
|
|
1,777 |
|
|
|
2,486 |
|
Long-term debt, net |
|
|
3,988 |
|
|
|
3,987 |
|
Operating lease liabilities |
|
|
196 |
|
|
|
206 |
|
Long-term environmental remediation |
|
|
448 |
|
|
|
461 |
|
Deferred income taxes |
|
|
41 |
|
|
|
44 |
|
Other liabilities |
|
|
354 |
|
|
|
328 |
|
Total liabilities |
|
|
6,804 |
|
|
|
7,512 |
|
Commitments and contingent liabilities |
|
|
|
|
||||
Equity |
|
|
|
|
||||
Common stock (par value |
|
|
2 |
|
|
|
2 |
|
Treasury stock, at cost (48,889,448 shares at September 30, 2024 and 48,932,387 at December 31, 2023) |
|
|
(1,805 |
) |
|
|
(1,806 |
) |
Additional paid-in capital |
|
|
1,050 |
|
|
|
1,033 |
|
Retained earnings |
|
|
1,763 |
|
|
|
1,782 |
|
Accumulated other comprehensive loss |
|
|
(353 |
) |
|
|
(274 |
) |
Total Chemours stockholders’ equity |
|
|
657 |
|
|
|
737 |
|
Non-controlling interests |
|
|
2 |
|
|
|
2 |
|
Total equity |
|
|
659 |
|
|
|
739 |
|
Total liabilities and equity |
|
$ |
7,463 |
|
|
$ |
8,251 |
|
The Chemours Company |
||||||||
Consolidated Statements of Cash Flows (Unaudited) |
||||||||
(Dollars in millions) |
||||||||
|
|
Nine Months Ended September 30, |
||||||
|
|
2024 |
|
2023 |
||||
Cash flows from operating activities |
|
|
|
|
||||
Net income (loss) |
|
$ |
94 |
|
|
$ |
(220 |
) |
Adjustments to reconcile net income to cash used for operating activities: |
|
|
|
|
||||
Depreciation and amortization |
|
|
223 |
|
|
|
233 |
|
Gain on sales of assets and businesses |
|
|
(3 |
) |
|
|
(106 |
) |
Equity in earnings of affiliates, net |
|
|
(31 |
) |
|
|
(32 |
) |
Loss on extinguishment of debt |
|
|
— |
|
|
|
1 |
|
Amortization of debt issuance costs and issue discounts |
|
|
9 |
|
|
|
6 |
|
Deferred tax benefit |
|
|
(34 |
) |
|
|
(137 |
) |
Asset-related charges |
|
|
25 |
|
|
|
89 |
|
Stock-based compensation expense |
|
|
12 |
|
|
|
13 |
|
Net periodic pension cost |
|
|
2 |
|
|
|
8 |
|
Defined benefit plan contributions |
|
|
(9 |
) |
|
|
(9 |
) |
Other operating charges and credits, net |
|
|
(9 |
) |
|
|
(15 |
) |
Goodwill impairment |
|
|
56 |
|
|
|
— |
|
Decrease (increase) in operating assets: |
|
|
|
|
||||
Accounts and notes receivable, net |
|
|
(348 |
) |
|
|
(212 |
) |
Inventories and other current operating assets |
|
|
(91 |
) |
|
|
71 |
|
Other non-current operating assets |
|
|
48 |
|
|
|
59 |
|
(Decrease) increase in operating liabilities: |
|
|
|
|
||||
Accounts payable |
|
|
(95 |
) |
|
|
(333 |
) |
Other current operating liabilities |
|
|
(624 |
) |
|
|
660 |
|
Other non-current operating liabilities |
|
|
4 |
|
|
|
(2 |
) |
Cash (used for) provided by operating activities |
|
|
(771 |
) |
|
|
74 |
|
Cash flows from investing activities |
|
|
|
|
||||
Purchases of property, plant, and equipment |
|
|
(251 |
) |
|
|
(235 |
) |
Proceeds from sales of assets and businesses |
|
|
3 |
|
|
|
138 |
|
Foreign exchange contract settlements, net |
|
|
— |
|
|
|
(8 |
) |
Other investing activities |
|
|
2 |
|
|
|
6 |
|
Cash used for investing activities |
|
|
(246 |
) |
|
|
(99 |
) |
Cash flows from financing activities |
|
|
|
|
||||
Proceeds from issuance of debt |
|
|
— |
|
|
|
648 |
|
Debt repayments |
|
|
(13 |
) |
|
|
(277 |
) |
Payments of debt issuance cost |
|
|
— |
|
|
|
(4 |
) |
Payments on finance leases |
|
|
(9 |
) |
|
|
(8 |
) |
Proceeds from supplier financing program |
|
|
67 |
|
|
|
70 |
|
Payments to supplier financing program |
|
|
(80 |
) |
|
|
(72 |
) |
Purchases of treasury stock, at cost |
|
|
— |
|
|
|
(69 |
) |
Proceeds from exercised stock options, net |
|
|
8 |
|
|
|
18 |
|
Payments related to tax withholdings on vested stock awards |
|
|
(3 |
) |
|
|
(18 |
) |
Payments of dividends to the Company's common shareholders |
|
|
(112 |
) |
|
|
(112 |
) |
Cash received from non-controlling interest shareholder |
|
|
— |
|
|
|
1 |
|
Other financing activities |
|
|
21 |
|
|
|
— |
|
Cash (used for) provided by financing activities |
|
|
(121 |
) |
|
|
177 |
|
Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents |
|
|
(3 |
) |
|
|
(9 |
) |
(Decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents |
|
|
(1,141 |
) |
|
|
143 |
|
Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1, |
|
|
1,807 |
|
|
|
1,304 |
|
Cash, cash equivalents, restricted cash and restricted cash equivalents at September 30, |
|
$ |
666 |
|
|
$ |
1,447 |
|
|
|
|
|
|
||||
Supplemental cash flows information |
|
|
|
|
||||
Non-cash investing and financing activities: |
|
|
|
|
||||
Purchases of property, plant, and equipment included in accounts payable |
|
$ |
92 |
|
|
$ |
76 |
|
Certain prior period amounts have been revised to correct for certain immaterial errors impacting previously issued financial statements, which are more fully described in our Annual Report on Form 10-K for the year ended December 31, 2023. Certain prior period amounts have been reclassified to conform to the current period presentation, the effect of which was not material to the Company’s interim consolidated financial statements.
The Chemours Company |
||||||||||||||||||||||||
Segment Financial and Operating Data (Unaudited) |
||||||||||||||||||||||||
(Dollars in millions) |
||||||||||||||||||||||||
Segment Net Sales |
|
|
|
|
|
|
|
|
|
|
|
Three Months |
|
|
|
|
||||||||
|
|
|
|
|
|
Ended |
|
|
Sequential |
|||||||||||||||
|
Three Months Ended September 30, |
|
|
Increase / |
|
June 30, |
|
|
Increase / |
|||||||||||||||
|
2024 |
|
|
2023 |
|
|
(Decrease) |
|
2024 |
|
|
(Decrease) |
||||||||||||
Thermal & Specialized Solutions |
$ |
|
460 |
|
|
$ |
|
436 |
|
|
$ |
|
24 |
|
|
$ |
|
513 |
|
|
$ |
|
(53 |
) |
Titanium Technologies |
|
|
679 |
|
|
|
|
690 |
|
|
|
|
(11 |
) |
|
|
|
673 |
|
|
|
|
6 |
|
Advanced Performance Materials |
|
|
348 |
|
|
|
|
343 |
|
|
|
|
5 |
|
|
|
|
339 |
|
|
|
|
9 |
|
Other Segment |
|
|
14 |
|
|
|
|
18 |
|
|
|
|
(4 |
) |
|
|
|
13 |
|
|
|
|
1 |
|
Total Net Sales |
$ |
|
1,501 |
|
|
$ |
|
1,487 |
|
|
$ |
|
14 |
|
|
$ |
|
1,538 |
|
|
$ |
|
(37 |
) |
Segment Adjusted EBITDA |
|
|
|
|
|
|
|
|
Three Months |
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Ended |
|
|
Sequential |
|||||||||
|
Three Months Ended September 30, |
|
|
Increase / |
|
June 30, |
|
|
Increase / |
|||||||||||||||
|
2024 |
|
|
2023 |
|
|
(Decrease) |
|
2024 |
|
|
(Decrease) |
||||||||||||
Thermal & Specialized Solutions |
$ |
|
141 |
|
|
$ |
|
162 |
|
|
$ |
|
(21 |
) |
|
$ |
|
161 |
|
|
$ |
|
(20 |
) |
Titanium Technologies |
$ |
|
85 |
|
|
$ |
|
69 |
|
|
$ |
|
16 |
|
|
$ |
|
80 |
|
|
$ |
|
5 |
|
Advanced Performance Materials |
$ |
|
39 |
|
|
$ |
|
68 |
|
|
$ |
|
(29 |
) |
|
$ |
|
45 |
|
|
$ |
|
(6 |
) |
Other Segment |
$ |
|
3 |
|
|
$ |
|
2 |
|
|
$ |
|
1 |
|
|
$ |
|
3 |
|
|
$ |
|
— |
|
Quarterly Change in Net Sales from the three months ended September 30, 2023 |
|
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
September 30, |
|
|
Percentage Change |
|
|
|
|||||||||||||
2024 |
vs. |
Percentage Change Due To |
||||||||||||||||||
|
Net Sales |
|
|
September 30, 2023 |
|
Price |
|
Volume |
|
Currency |
|
Portfolio |
|
|||||||
Total Company |
$ |
|
1,501 |
|
|
|
1 |
% |
|
(3 |
)% |
|
5 |
% |
|
(1 |
)% |
|
— |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Thermal & Specialized Solutions |
$ |
|
460 |
|
|
|
6 |
% |
|
(2 |
)% |
|
8 |
% |
|
— |
% |
|
— |
% |
Titanium Technologies |
|
|
679 |
|
|
|
(2 |
)% |
|
(2 |
)% |
|
1 |
% |
|
(1 |
)% |
|
— |
% |
Advanced Performance Materials |
|
|
348 |
|
|
|
1 |
% |
|
(7 |
)% |
|
9 |
% |
|
(1 |
)% |
|
— |
% |
Other Segment |
|
|
14 |
|
|
|
(22 |
)% |
|
— |
% |
|
14 |
% |
|
— |
% |
|
(36 |
)% |
Quarterly Change in Net Sales from the three months ended June 30, 2024 |
|
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
September 30, |
|
|
Percentage Change |
|
|
|
|||||||||||||
2024 |
vs. |
Percentage Change Due To |
||||||||||||||||||
|
Net Sales |
|
|
June 30, 2024 |
|
Price |
|
Volume |
|
Currency |
|
Portfolio |
|
|||||||
Total Company |
$ |
|
1,501 |
|
|
(2 |
)% |
— |
% |
(2 |
)% |
— |
% |
— |
% |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Thermal & Specialized Solutions |
$ |
|
460 |
|
|
|
(10 |
)% |
|
(2 |
)% |
|
(8 |
)% |
|
— |
% |
|
— |
% |
Titanium Technologies |
|
|
679 |
|
|
|
1 |
% |
|
1 |
% |
|
— |
% |
|
— |
% |
|
— |
% |
Advanced Performance Materials |
|
|
348 |
|
|
|
3 |
% |
|
— |
% |
|
3 |
% |
|
— |
% |
|
— |
% |
Other Segment |
|
|
14 |
|
|
|
8 |
% |
|
8 |
% |
|
— |
% |
|
— |
% |
|
— |
% |
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions)
GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation
Adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) is defined as (loss) income before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset-related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company’s ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net (loss) income attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.
|
|
Three Months Ended |
|
Nine Months Ended |
|
Twelve Months Ended |
|||||||||||||||||||||||||||||
|
|
September 30, |
|
June 30, |
|
September 30, |
|
September 30, |
|||||||||||||||||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|||||||||||||||||||||
(Loss) income before income taxes |
|
$ |
|
(30 |
) |
|
$ |
|
13 |
|
|
$ |
|
82 |
|
|
$ |
|
118 |
|
|
$ |
|
(247 |
) |
|
$ |
|
48 |
|
|
$ |
|
(316 |
) |
Net (loss) income attributable to Chemours |
|
$ |
|
(27 |
) |
|
$ |
|
12 |
|
|
$ |
|
70 |
|
|
$ |
|
94 |
|
|
$ |
|
(220 |
) |
|
$ |
|
77 |
|
|
$ |
|
(316 |
) |
Non-operating pension and other post-retirement employee benefit (income) cost |
|
|
|
(2 |
) |
|
|
|
1 |
|
|
|
|
(2 |
) |
|
|
|
(4 |
) |
|
|
|
1 |
|
|
|
|
(6 |
) |
|
|
|
— |
|
Exchange losses, net |
|
|
|
— |
|
|
|
|
9 |
|
|
|
|
7 |
|
|
|
|
6 |
|
|
|
|
21 |
|
|
|
|
23 |
|
|
|
|
47 |
|
Restructuring, asset-related, and other charges (1) |
|
|
|
43 |
|
|
|
|
127 |
|
|
|
|
3 |
|
|
|
|
51 |
|
|
|
|
142 |
|
|
|
|
61 |
|
|
|
|
143 |
|
Goodwill impairment charge (2) |
|
|
|
56 |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
56 |
|
|
|
|
— |
|
|
|
|
56 |
|
|
|
|
— |
|
Loss on extinguishment of debt |
|
|
|
— |
|
|
|
|
1 |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
1 |
|
|
|
|
— |
|
|
|
|
1 |
|
Gain on sales of assets and businesses, net (3) |
|
|
|
— |
|
|
|
|
(106 |
) |
|
|
|
— |
|
|
|
|
(3 |
) |
|
|
|
(106 |
) |
|
|
|
(7 |
) |
|
|
|
(101 |
) |
Transaction costs (4) |
|
|
|
— |
|
|
|
|
7 |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
7 |
|
|
|
|
9 |
|
|
|
|
7 |
|
Qualified spend recovery (5) |
|
|
|
(7 |
) |
|
|
|
(11 |
) |
|
|
|
(8 |
) |
|
|
|
(22 |
) |
|
|
|
(43 |
) |
|
|
|
(33 |
) |
|
|
|
(60 |
) |
Litigation-related charges (6) |
|
|
|
1 |
|
|
|
|
31 |
|
|
|
|
(16 |
) |
|
|
|
(15 |
) |
|
|
|
675 |
|
|
|
|
74 |
|
|
|
|
714 |
|
Environmental charges (7) |
|
|
|
— |
|
|
|
|
8 |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
9 |
|
|
|
|
— |
|
|
|
|
31 |
|
Adjustments made to income taxes (8) |
|
|
|
1 |
|
|
|
|
(1 |
) |
|
|
|
(4 |
) |
|
|
|
(2 |
) |
|
|
|
(5 |
) |
|
|
|
(15 |
) |
|
|
|
34 |
|
(Benefit from) provision for income taxes relating to reconciling items (9) |
|
|
|
(4 |
) |
|
|
|
(13 |
) |
|
|
|
7 |
|
|
|
|
5 |
|
|
|
|
(104 |
) |
|
|
|
(27 |
) |
|
|
|
(120 |
) |
Adjusted Net Income |
|
|
|
61 |
|
|
|
|
65 |
|
|
|
|
57 |
|
|
|
|
166 |
|
|
|
|
378 |
|
|
|
|
212 |
|
|
|
|
380 |
|
Net income attributable to non-controlling interests |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
1 |
|
|
|
|
— |
|
|
|
|
1 |
|
Interest expense, net |
|
|
|
69 |
|
|
|
|
55 |
|
|
|
|
66 |
|
|
|
|
197 |
|
|
|
|
145 |
|
|
|
|
261 |
|
|
|
|
186 |
|
Depreciation and amortization |
|
|
|
78 |
|
|
|
|
76 |
|
|
|
|
74 |
|
|
|
|
223 |
|
|
|
|
233 |
|
|
|
|
297 |
|
|
|
|
307 |
|
All remaining provision for income taxes (9) |
|
|
|
— |
|
|
|
|
15 |
|
|
|
|
9 |
|
|
|
|
21 |
|
|
|
|
81 |
|
|
|
|
13 |
|
|
|
|
84 |
|
Adjusted EBITDA |
|
$ |
|
208 |
|
|
$ |
|
211 |
|
|
$ |
|
206 |
|
|
$ |
|
607 |
|
|
$ |
|
838 |
|
|
$ |
|
783 |
|
|
$ |
|
958 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Total debt principal |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
|
4,078 |
|
|
$ |
|
4,031 |
|
||||||||||
Less: Cash and cash equivalents |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(596 |
) |
|
|
|
(852 |
) |
||||||||||
Total debt principal, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
|
3,482 |
|
|
$ |
|
3,179 |
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Net Leverage Ratio (calculated using GAAP earnings) (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
72.5x |
|
|
|
(10.1)x |
|||||||||||||
Net Leverage Ratio (calculated using Non-GAAP earnings) (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.4x |
|
|
|
3.3x |
|
GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation (Continued)
(1) |
For the twelve months ended September 30, 2024, restructuring, asset-related, and other charges primarily includes charges related to the 2024 Restructuring Program, Titanium Technologies Transformation Plan and shutdown of a production line at the Company's |
|
(2) |
Represents a non-cash goodwill impairment charge in the Advanced Performance Materials reporting unit, which is discussed further in "Note 11 – Goodwill and Other Intangibles, Net" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. |
|
(3) |
For the twelve months ended September 30, 2024, gain on sales of assets and businesses, net includes pre-tax gain on sale of |
|
(4) |
For the twelve months ended September 30, 2024, transaction costs includes |
|
(5) |
Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 18 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. |
|
(6) |
Litigation-related charges pertains to litigation settlements, PFOA drinking water treatment accruals, and other related legal fees. For the twelve months ended September 30, 2024, litigation-related charges primarily includes a |
|
(7) |
Environmental charges pertains to management’s assessment of estimated liabilities associated with certain environmental remediation expenses at various sites. For the twelve months ended September 30, 2023, environmental charges include |
|
(8) |
Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items. |
|
(9) |
The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure. |
|
(10) |
Net Leverage Ratio calculated using GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by (loss) income before income taxes. Net Leverage Ratio calculated using non-GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA. |
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)
GAAP (Loss) Earnings per Share to Adjusted Earnings per Share Reconciliation
Adjusted earnings per share (“Adjusted EPS”) is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which includes unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.
|
|
Three Months Ended |
|
Nine Months Ended |
|||||||||||
|
|
September 30, |
|
June 30, |
|
September 30, |
|||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2024 |
|
2023 |
|||||
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
||||
Net (loss) income attributable to Chemours |
|
$ |
(27) |
|
$ |
12 |
|
$ |
70 |
|
$ |
94 |
|
$ |
(220) |
Adjusted Net Income |
|
|
61 |
|
|
65 |
|
|
57 |
|
|
166 |
|
|
378 |
Denominator: |
|
|
|
|
|
|
|
|
|
|
|||||
Weighted-average number of common shares outstanding - basic |
|
|
149,697,616 |
|
|
148,623,633 |
|
|
149,413,167 |
|
|
149,383,146 |
|
|
148,929,580 |
Dilutive effect of the Company's employee compensation plans (1) |
|
|
482,579 |
|
|
1,562,005 |
|
|
709,893 |
|
|
735,880 |
|
|
1,753,788 |
Weighted-average number of common shares outstanding - diluted (1) |
|
|
150,180,195 |
|
|
150,185,638 |
|
|
150,123,060 |
|
|
150,119,026 |
|
|
150,683,368 |
|
|
|
|
|
|
|
|
|
|
|
|||||
Basic (loss) earnings per share of common stock (2) |
|
$ |
(0.18) |
|
$ |
0.08 |
|
$ |
0.47 |
|
$ |
0.63 |
|
$ |
(1.47) |
Diluted (loss) earnings per share of common stock (1) (2) |
|
|
(0.18) |
|
|
0.08 |
|
|
0.46 |
|
|
0.63 |
|
|
(1.47) |
Adjusted basic earnings per share of common stock (2) |
|
|
0.40 |
|
|
0.44 |
|
|
0.38 |
|
|
1.11 |
|
|
2.55 |
Adjusted diluted earnings per share of common stock (1) (2) |
|
|
0.40 |
|
|
0.43 |
|
|
0.38 |
|
|
1.10 |
|
|
2.52 |
(1) |
In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under |
|
(2) |
Figures may not recalculate exactly due to rounding. Basic and diluted (loss) earnings per share are calculated based on unrounded numbers. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104977465/en/
INVESTORS
Brandon Ontjes
Vice President, Investor Relations
+1.302.773.3309
investor@chemours.com
Kurt Bonner
Manager, Investor Relations
+1.302.773.0026
investor@chemours.com
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com
Source: The Chemours Company
FAQ
What were Chemours (CC) Q3 2024 earnings per share?
How much cost savings is Chemours (CC) targeting in its new strategy?
What was Chemours (CC) Q3 2024 revenue?